22-25 July 2007 │ Sydney, Australia
Coverage of Microbicides at IAS
The fourth conference in the HIV Pathogenesis, Treatment and Prevention series, IAS 2007, featured reports on the latest developments in the areas of basic, clinical, and prevention science. View selected news coverage of key events presented at the conference.
View scientific coverage of microbicide research presented at IAS 2007 in The Microbicide Quarterly.
Kaisernetwork.org Coverage:
Selected Sessions on Microbicides
Daily Scientific Updates
View More IAS 2007 Coverage from kaisernetwork.org
Conference Information
Website: http://www.ias2007.org/
| Important Dates |
| Early Registration |
1 February 2007 |
| Abstract Submission |
7 March 2007 |
| General Registration |
10 May 2007 |
| Conference |
22-25 July 2007 |
Program, Abstracts & Speakers
Program at-a-Glance
Search Website & Abstracts
View Webcasts & Podcasts
Overview
More than 5,000 delegates from 140 countries attended the 4th IAS Conference on HIV Pathogenesis, Treatment and Prevention (IAS 2007) held in Sydney, Australia on 22 - 25 July 2007. The International AIDS Society (IAS) organized the conference to provide new insights into HIV disease development, prevention, and care that can lead to novel research directions, help advance translation research, and move theoretic advances into clinical practice and prevention programs.
Track A: HIV Basic Science
This track encompasses all aspects of fundamental HIV biology and the host response to HIV. Areas of focus include HIV infection and replication, transmission, genetics, evolution, structure and function, pathogenesis, adaptive and innate immune responses to HIV, genetic susceptibility to HIV, co-infection, and progress in animal models. Pre-clinical vaccine, microbicide and drug development are important themes of this track.
Track B: Clinical Research, Treatment and Care
This track highlights the latest research findings, complexities and controversies related to the diagnosis, natural history and management of HIV infection; prevention, diagnosis and treatment of opportunistic infections; co-infection and other co-morbidities; antiretroviral therapy and immunotherapy. Issues for discussion related to antiretroviral therapy include new drug therapies, pharmacokinetics, drug interactions, adherence, short- and long-term adverse events, clade types and drug resistance. Other important issues includes approaches to treatment, care and support in specific populations including infants and children, adolescents, women (including prevention of mother-to-child transmission), marginalized groups and innovations related to diagnosis and to provision of HIV care in resource-limited settings.
Track C: Biomedical Prevention
This track focuses on HIV/AIDS prevention research and issues related to the design, implementation and evaluation of prevention programs. It includes an examination of methodological and programmatic advances in the continuum of prevention research, particularly best practices in HIV prevention for vulnerable populations in resource-limited settings. It also features strategies to increase HIV prevention capacity, approaches to translate prevention research into practice, efforts to promote preparedness for biomedical prevention technologies, and research on new prevention approaches including microbicides, vaccines, pre-and post exposure prophylaxis, circumcision and other methods.
